Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis

Deoxynivalenol (DON) is a mycotoxin commonly found worldwide and is implicated in various health effects. We recently demonstrated that subacute oral exposure to DON significantly exacerbates symptoms of type 2 helper T-cell-mediated allergic diseases in a model. We aim to investigate the role of or...

Full description

Saved in:
Bibliographic Details
Main Authors: Takayoshi Miyamoto, Mariko Komuro, Ryota Aihara, Chiharu Ohira, Mao Kaneki, Naoki Iwashita, Yoshiichi Takagi, Atsushi Miyasaka, Masayo Kushiro, Shiro Miyake, Tomoki Fukuyama
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Toxins
Subjects:
Online Access:https://www.mdpi.com/2072-6651/17/2/47
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850078527012995072
author Takayoshi Miyamoto
Mariko Komuro
Ryota Aihara
Chiharu Ohira
Mao Kaneki
Naoki Iwashita
Yoshiichi Takagi
Atsushi Miyasaka
Masayo Kushiro
Shiro Miyake
Tomoki Fukuyama
author_facet Takayoshi Miyamoto
Mariko Komuro
Ryota Aihara
Chiharu Ohira
Mao Kaneki
Naoki Iwashita
Yoshiichi Takagi
Atsushi Miyasaka
Masayo Kushiro
Shiro Miyake
Tomoki Fukuyama
author_sort Takayoshi Miyamoto
collection DOAJ
description Deoxynivalenol (DON) is a mycotoxin commonly found worldwide and is implicated in various health effects. We recently demonstrated that subacute oral exposure to DON significantly exacerbates symptoms of type 2 helper T-cell-mediated allergic diseases in a model. We aim to investigate the role of oral DON exposure in type 17 helper T-cell-mediated immunoreactive diseases using a mouse psoriasis model. Psoriasis was induced by the dermal administration of 5% imiquimod in female BALB/c mice. A standard rodent diet was supplemented with DON to achieve a final concentration of 0.3 ppm (1.5 μg/kg bw/day), which was administered daily for 14 days. Skin thickness, scratching behavior, and transepidermal water loss (TEWL) were continuously measured during imiquimod administration. Mice exposed to DON exhibited significant increases in skin thickness, TEWL, and scratching behavior. Histological evaluations revealed aggravated hyperplasia, neutrophil infiltration, and inflammatory cell accumulation in the dermis. Furthermore, DON exposure significantly increased the number of CD4+ helper T cells and CD11c+ MHC class II+ dendritic cells in the auricular lymph nodes, along with elevated TNF-α and IL-17 levels in stimulated T cells. The gene expression of IL-17 in skin tissue was also significantly up-regulated in DON-treated mice. Collectively, these findings suggest that oral exposure to DON aggravates symptoms in a mouse psoriasis model.
format Article
id doaj-art-c292912c72a84ba0beffb9a66748eab5
institution DOAJ
issn 2072-6651
language English
publishDate 2025-01-01
publisher MDPI AG
record_format Article
series Toxins
spelling doaj-art-c292912c72a84ba0beffb9a66748eab52025-08-20T02:45:31ZengMDPI AGToxins2072-66512025-01-011724710.3390/toxins17020047Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced PsoriasisTakayoshi Miyamoto0Mariko Komuro1Ryota Aihara2Chiharu Ohira3Mao Kaneki4Naoki Iwashita5Yoshiichi Takagi6Atsushi Miyasaka7Masayo Kushiro8Shiro Miyake9Tomoki Fukuyama10School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanSchool of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanSchool of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanSchool of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanSchool of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanSchool of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanSchool of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanKyushu Okinawa Agricultural Research Center, National Agriculture and Food Research Organization (NARO), Suya 2421, Koshi 861-1192, Kumamoto, JapanInstitute of Food Research, NARO, 2-1-12 Kannondai, Tsukuba 305-8642, Ibaraki, JapanDepartment of Food and Life Science, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanSchool of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara-shi 252-5201, Kanagawa, JapanDeoxynivalenol (DON) is a mycotoxin commonly found worldwide and is implicated in various health effects. We recently demonstrated that subacute oral exposure to DON significantly exacerbates symptoms of type 2 helper T-cell-mediated allergic diseases in a model. We aim to investigate the role of oral DON exposure in type 17 helper T-cell-mediated immunoreactive diseases using a mouse psoriasis model. Psoriasis was induced by the dermal administration of 5% imiquimod in female BALB/c mice. A standard rodent diet was supplemented with DON to achieve a final concentration of 0.3 ppm (1.5 μg/kg bw/day), which was administered daily for 14 days. Skin thickness, scratching behavior, and transepidermal water loss (TEWL) were continuously measured during imiquimod administration. Mice exposed to DON exhibited significant increases in skin thickness, TEWL, and scratching behavior. Histological evaluations revealed aggravated hyperplasia, neutrophil infiltration, and inflammatory cell accumulation in the dermis. Furthermore, DON exposure significantly increased the number of CD4+ helper T cells and CD11c+ MHC class II+ dendritic cells in the auricular lymph nodes, along with elevated TNF-α and IL-17 levels in stimulated T cells. The gene expression of IL-17 in skin tissue was also significantly up-regulated in DON-treated mice. Collectively, these findings suggest that oral exposure to DON aggravates symptoms in a mouse psoriasis model.https://www.mdpi.com/2072-6651/17/2/47deoxynivalenolmycotoxinpsoriasisIL-17TNF-α
spellingShingle Takayoshi Miyamoto
Mariko Komuro
Ryota Aihara
Chiharu Ohira
Mao Kaneki
Naoki Iwashita
Yoshiichi Takagi
Atsushi Miyasaka
Masayo Kushiro
Shiro Miyake
Tomoki Fukuyama
Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis
Toxins
deoxynivalenol
mycotoxin
psoriasis
IL-17
TNF-α
title Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis
title_full Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis
title_fullStr Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis
title_full_unstemmed Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis
title_short Short-Term Oral Administration of 1.5 μg/kg bw/day of Deoxynivalenol Significantly Exacerbates Inflammatory and Itching Symptoms in a Mouse Model of Imiquimod-Induced Psoriasis
title_sort short term oral administration of 1 5 μg kg bw day of deoxynivalenol significantly exacerbates inflammatory and itching symptoms in a mouse model of imiquimod induced psoriasis
topic deoxynivalenol
mycotoxin
psoriasis
IL-17
TNF-α
url https://www.mdpi.com/2072-6651/17/2/47
work_keys_str_mv AT takayoshimiyamoto shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT marikokomuro shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT ryotaaihara shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT chiharuohira shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT maokaneki shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT naokiiwashita shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT yoshiichitakagi shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT atsushimiyasaka shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT masayokushiro shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT shiromiyake shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis
AT tomokifukuyama shorttermoraladministrationof15mgkgbwdayofdeoxynivalenolsignificantlyexacerbatesinflammatoryanditchingsymptomsinamousemodelofimiquimodinducedpsoriasis